Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Copanlisib in Hepatic or Renal Impairment
NCT03172884Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of copanlisib in follicular lymphoma (FL) (4 arms), sponsored by Bayer. Primary endpoints: Maximum Observed Concentration of Copanlisib in Plasma at 168 hours, Area Under the Concentration vs. Time Curve From Zero to Infinity of Copanlisib in Plasma at 168 hours and 1 more. Started Jun 2017; status: completed.
02
Drugs
copanlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03172884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172884.